BILIARY DISEASE

Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis

C Raetsch, J D Jia, G Boigk, M Bauer, E G Hahn, E-O Riecken, D Schuppan


Background: The trisubstituted methylxanthine derivative pentoxifylline inhibits hepatic stellate cell proliferation and collagen synthesis in vitro. The antifibrotic effect of pentoxifylline in a suitable in vivo model of chronic liver fibrogenesis remains to be tested.

Methods: Groups of adult rats (n=20–23) received oral pentoxifylline at a dose of 8 mg/kg/day from week 1 to week 6, and 16 mg/kg/day from week 1 to week 6 or week 4 to week 6 after complete bile duct occlusion. Animals who underwent sham operation that received 16 mg/kg/day pentoxifylline and untreated rats with bile duct occlusion alone served as controls. After six weeks, animals were sacrificed and parameters of fibrogenesis determined.

Results: Bile duct occlusion caused portal cirrhosis with a 10-fold increased hepatic collagen content in the absence of inflammation or necrosis. This was accompanied by an 11-fold elevated serum amino-terminal procollagen III peptide (PIIINP). The drug induced a dramatic eightfold downregulation of procollagen I mRNA, and suppression of the fibrogenic factors transforming growth factor β1 and connective tissue growth factor by 60–70%. However, profibrogenic tissue inhibitor of metalloproteinase 1 (TIMP-1) mRNA was increased twofold, resulting in only a moderate decrease in liver collagen, fibrosis score, and PIIINP.

Conclusions: We conclude that targeting pentoxifylline to the fibrogenic cells, thereby avoiding upregulation of TIMP-1, could become a potent antifibrogenic tool in chronic liver disease.

Curative or preventive treatment is only available for a minority of patients with chronic liver disease. Currently, there is no established therapy to halt the progression of liver fibrosis or to induce regression of cirrhosis. In order to prove an in vivo antifibrotic effect of drugs that can suppress collagen synthesis in vitro, animal models that resemble human chronic liver diseases have to be used. Complete occlusion of the extra and intrahepatic biliary system in rats generates a progressive portal fibrosis and, ultimately, cirrhosis, that is essentially devoid of hepatocyte necrosis or major inflammation. This model is suitable for detecting drugs that are truly antifibrotic in vivo, at least in biliary fibrosis, the effect of which is not obscured by their activities as radical scavengers or antiphlogistics, both properties which have been shown to be ineffective in preventing the progression of fibrosis in humans.

Pentoxifylline (PTX) is a trimethylated xanthine derivative which is widely used in disorders of vascular perfusion due to its favourable effects on erythrocyte deformability, erythrocyte oxygen delivery, and its properties as a peripheral vasodilator. PTX also improves liver perfusion in humans. As with other methylxanthines, PTX is an inhibitor of phosphodiesterases, resulting in an elevated intracellular pool of the second messenger cyclic adenosine monophosphate (cAMP). In vitro studies with fibroblasts have shown that PTX potently reduces cell proliferation, stimulates interstitial collagenase activity, and suppresses the synthesis, secretion, and deposition of fibrillar collagen type I and III, proteoglycans, and fibronectin. More recently, an antifibrogenic effect of PTX on activated hepatic stellate or myofibroblast-like cells, which are responsible for the excessive extracellular matrix production in liver fibrosis, has been demonstrated. These studies concluded that PTX might exert its in vitro antifibrogenic effect on hepatic stellate cells primarily by inhibiting procollagen I and III mRNA expression and by downregulating the stellate cell mitogen platelet derived growth factor, events which were correlated with an increase in cellular levels of cAMP.

The activities of PTX, affecting cell membranes, cytokine and growth factor signalling, as well as mesenchymal cell proliferation and collagen synthesis, coupled with its well explored safety profile, make testing of its antifibrotic properties in the more complex context of a suitable in vivo model of progressive hepatic fibrosis mandatory. In a previous study, using a model of porcine liver fibrosis induced by feeding yellow phosphorus, PTX reduced the increased liver collagen content only moderately, from 144% to 113% of controls. As the number of animals per group was low (n=3), the model is pathophysiologically unrelated to human liver fibrosis, and as expression of profibrogenic genes was not investigated, interpretation of the data is difficult.

Using the model of chronic rat secondary biliary fibrosis, we demonstrated that doses of PTX comparable with those administered for human vascular disorders caused an unexpected eightfold downregulation of hepatic procollagen type I mRNA, and significant suppression of hepatic expression of two central fibrogenic cytokines, transforming growth factor β1 (TGF-β1) and connective tissue growth factor (CTGF). However, a concomitant increase in tissue inhibitor of metalloproteinase-1 (TIMP-1) mRNA reduced the antifibrotic effect of PTX. Derivatives of PTX targeted to the fibrogenic cells of the liver or that lack TIMP-1 upregulating activity could become potent antifibrotic agents in chronic liver diseases.
Adult female Wistar rats (Schoenwalde, Germany) weighing 199 ± 20 g were maintained in 12 hour light/dark cycles at 23°C, with 60% ± 20% humidity. Complete bile duct occlusion (BDO) was performed as reported previously. Briefly, after midline abdominal incision and proper isolation, the common bile duct was occluded by injection of sodium amidotriazolate (Ethibloc 0.2 ml/kg body weight; Ethicon, Germany) in a retrograde direction using a Teflon catheter (Abbocath-T 26 G; Abbott, Chicago, Illinois, USA), followed by double ligation and siccision in-between. Sham operation was a midline abdominal incision, isolation of the common bile duct, and wound closure. PTX (Trental; Aventis, Germany) was added to the drinking water and did not alter fluid consumption by the animals. The PTX (Trental; Aventis, Germany) was added to the drinking water and did not alter fluid consumption by the animals. The water and did not alter fluid consumption by the animals.

METHODS

Rat model of secondary biliary cirrhosis

After six weeks, animals were sacrificed and aliquots of right and left liver lobes snap frozen in liquid nitrogen. All animal experimentation was carried out in accordance with our institutional and governmental regulations on the use of experimental animals. After six weeks, rats were sacrificed under anaesthesia by puncture of the right ventricle and exsanguination. Heart, liver, spleen, and kidneys were weighed, and 1–2 g pieces of the left and right liver lobes fixed in 4% formalin for histology and hydroxyproline (HYP) determinations. Early mortality (within one hour to three days) of rats with BDO due to local infection was 9%. As significant fibrosis becomes evident only after two weeks of BDO, these animals were not considered for statistical analysis.

Histological scoring

For each liver, 1 µm paraffin sections of the right and left lobes were stained with haematoxylin/eosin, trichrome (Masson-Goldner), and silver impregnation (Gomori), and scores (see below) of both lobes averaged. Inflammation and necrosis were graded according to the histological activity index of Knodell and colleagues. Staging of fibrosis followed the slightly modified method of Ruvart and colleagues which, contrary to conventional scores, is particularly suited for detecting slight changes in portal fibrosis: normal liver (0 points); increased collagen with some periporalstellate bile duct proliferations (1 point); increased collagen with incomplete septa that do not form porto-portal or porto-central connections (2 points); strongly increased collagen, more incomplete than complete septa (2.25 points); an equal number of incomplete and complete septa (2.5 points); more complete than incomplete septa (2.75 points); and (3) complete septa and less than 25% diffuse parenchymal fibrosis (3.25 points); complete septa and 25–50% diffuse parenchymal fibrosis (3.5 points); complete septa and 50–75% diffuse parenchymal fibrosis (3.75 points); and complete septa and more than 75% diffuse parenchymal fibrosis (4 points). Point scores from each animal were derived from the means of the right and left liver lobes.

Determination of hepatic hydroxyproline and serum aminoterminal procollagen III peptide

Hepatic HYP content was determined in duplicate from approximately 0.2 g hydrolysed tissue from the right and left liver lobes using the method of Jamall and colleagues with minor modifications. Liver collagen content was calculated from mean HYP concentration of both lobes (both lobes differed by less than 8%). Serum aminoterminal procollagen III peptide (PIIINP) was measured by a radioimmunoassay based on rat PIIINP, a monospecific rabbit antiserum to rat PIIINP and a goat antiserum to rabbit IgG, as detailed previously.

Table 1: Clinical, chemical and fibrosis parameters in treated and untreated groups of rats

Sham 16 w 1–6, BDO w 1–6, BDO 8 w 1–6, BDO 16 w 1–6, BDO 16 w 4–6

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Sham 16 w 1–6</th>
<th>BDO w 1–6</th>
<th>BDO 8 w 1–6</th>
<th>BDO 16 w 1–6</th>
<th>BDO 16 w 4–6</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST (U/l)</td>
<td>82.5 (50/95)</td>
<td>93.5 (81/154)</td>
<td>127* (108/162)</td>
<td>135* (106/161)</td>
<td>98.5 (93/135)</td>
</tr>
<tr>
<td>ALT (U/l)</td>
<td>19.0 (17/22)</td>
<td>25.5 (20/30)</td>
<td>26.0 (22/33)</td>
<td>26.5 (23/33)</td>
<td>26.0 (21/31)</td>
</tr>
<tr>
<td>γGT (U/l)</td>
<td>2.00 (1/0.2)</td>
<td>19.5 (18/23)</td>
<td>18.0 (15/24)</td>
<td>20.0 (18/26)</td>
<td>16.5 (16/23)</td>
</tr>
<tr>
<td>ALP (U/l)</td>
<td>77.5 (57/89)</td>
<td>275 (247/330)</td>
<td>317 (272/355)</td>
<td>262 (243/305)</td>
<td>312 (263/370)</td>
</tr>
<tr>
<td>Bili (µmol/l)</td>
<td>6.15 (5.7/6.8)</td>
<td>167 (138/199)</td>
<td>171 (162/192)</td>
<td>165 (145/180)</td>
<td>153 (128/178)</td>
</tr>
<tr>
<td>Crea (µmol/l)</td>
<td>42.0 (41/47)</td>
<td>32.0 (32/36)</td>
<td>34.0 (32/38)</td>
<td>32.0 (31/35)</td>
<td>40.0** (35/41)</td>
</tr>
<tr>
<td>Increase BW (%)</td>
<td>27.1 (6.8)</td>
<td>27.3 (11.5)</td>
<td>22.6 (8.9)</td>
<td>18.6* (9.5)</td>
<td>25.3 (10.3)</td>
</tr>
<tr>
<td>Liver weight (g)</td>
<td>8.63 (8.37)</td>
<td>25.1 (2.6)</td>
<td>23.3 (3.3)</td>
<td>21.4* (2.1)</td>
<td>24.9 (3.4)</td>
</tr>
<tr>
<td>Spleen weight (g)</td>
<td>0.63 (0.06)</td>
<td>1.83 (0.36)</td>
<td>1.60* (0.48)</td>
<td>1.38** (0.28)</td>
<td>1.81 (0.48)</td>
</tr>
</tbody>
</table>

Data are median [25th/75th percentiles]. Shown 16 w 1–6, sham operation and PTX at 16 mg/kg/day for six weeks; BDO w 1–6, bile duct occlusion alone for six weeks; BDO 8 w 1–6, bile duct occlusion and PTX at 8 mg/kg/day for six weeks; BDO 16 w 1–6, bile duct occlusion and PTX at 16 mg/kg/d for six weeks; BDO 16 w 4–6, bile duct occlusion for six weeks and PTX at 16 mg/kg/day from week 4 to week 6.

BW, body weight; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGT, gamma glutamyltransferase; ALP, alkaline phosphatase; Bili, bilirubin; Crea, creatinine.

Significances were calculated using the Mann Whitney rank sum test: *p<0.05, **p<0.01 versus untreated group (BDO alone).
cDNA probes and multiprobe RNase protection assay
A 1.3 kb PstI/HindIII fragment of plasmid α1R1 containing cDNA encoding rat procollagen α1(1), kindly provided by Dr D Rowe (Department of Pediatrics, University of Connecticut Health Center, Farmington, Connecticut 06032, USA), was subcloned into pGEM1. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and TGF-β1 plasmids were gifts from Dr XL Tian (Max Delbrueck Centre for Molecular Medicine, Berlin-Buch, Germany). For generation of all other probes, rat liver total RNA was reverse transcribed with SuperscriptII Reverse Transcriptase (Gibco Life Technologies, Freiburg, Germany) and oligo-dT primer according to the manufacturer’s instructions. The cDNA for rat TIMP-1 was generated by polymerase chain reaction (PCR) using a mixture of Taq and Pfu DNA polymerases (Gibco and Stratagene, Amsterdam, the Netherlands) and primers binding to positions 109–133 and 415–439 of the published sequence. Similarly, rat CTGF cDNA was amplified with primers CAA CCG CAA GTG TGG AGT GT and CTC CAG TCT GCA GAA GGT ATT G according to positions 398–417 and 806–827 of the mouse CTGF sequence (GenBank accession No M70642).”

RESULTS
A total of 84 of 93 rats survived beyond day 4 after BDO (early mortality 9%, with no mortality thereafter). Groups of 20–23 surviving rats received either no PTX (untreated BDO controls), PTX at a dose of 8 mg/kg/day (low), or 16 mg/kg/day (high) for six weeks, or PTX (high) from week 4 to week 6 of BDO. Ten sham operated rats given PTX (high) served as normal controls (fig 1). All rats with BDO became icteric after a few days and displayed severe secondary biliary fibrosis at sacrifice. Body weights increased in all groups over the six weeks but were significantly lower only in rats with BDO that received PTX (high) (table 1). Liver and spleen weights were elevated 2–3-fold in all rats with BDO compared with...
that received PTX (high) compared with untreated rats with non-fibrotic controls. However, animals with BDO that received 16 mg PTX exhibited significantly lower liver and kidney weights (table 2) but not with serological markers of inflammation and necrosis in any group of fibrotic rats (score of 0). To assess the effect of PTX on hepatic stellate cell/myofibroblast activation, sections were stained for desmin. When we counted the number of desmin positive cells in three high power fields both of (fibrotic) portal tracts and (non-fibrotic) centrilobular areas of each liver, we did not detect significant differences between groups with BDO (not shown).

At sacrifice, serum levels of PIIINP, a surrogate marker of liver fibrogenesis, were increased 11-fold after BDO compared with the sham operated controls. PIIINP was lowered significantly in both groups that received PTX over six weeks (p<0.05) but unchanged in the group treated from week 4 to week 6 (fig 2D).

Hepatic procollagen α1(I), TIMP-1, TGF-β1, CTGF, and GAPDH steady state mRNA levels were determined by multiprobe ribonuclease protection assays. The protected bands showed the expected sizes and there were no equivalent bands in the negative controls. After six weeks of BDO, hepatic procollagen α1(I), TIMP-1 and TGF-β1 mRNA, normalised to GAPDH mRNA, were highly increased relative to the sham operated controls (all p<0.001) (fig 3). PTX downregulated the 20-fold increased procollagen α1(I) mRNA by a factor of eight (p<0.001) whereas it upregulated TIMP-1 mRNA twofold (p<0.05). TGF-β1 and CTGF transcript levels were decreased by approximately 60–70% (fig 3).

Alkaline phosphatase (ALP), gamma glutamyl transpeptidase (γGT), and bilirubin were increased 3.5, 9, and 27-fold, respectively, in the BDO compared with the sham operated animals. These cholestasis parameters were not affected by treatment with PTX (table 1). Similarly, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), reflecting inflammation and necrosis, did not differ among groups except for a moderate elevation in AST in rats that received both doses of PTX for six weeks (p<0.05).

To investigate if one of the serum parameters reflected the decrease in hepatic collagen accumulation in animals treated with PTX, correlations were calculated using the Spearman rank order test (table 2). Liver hydroxyproline correlated well with PTX (high) over six weeks. Data are mean (SD). *p<0.05, **p<0.001 versus untreated group (BDO alone).

**DISCUSSION**

We previously showed that experimental liver fibrosis due to complete obstruction of the biliary tract is a suitable model for testing drugs that inhibit hepatic fibrogenesis in vivo. This model is characterised by a progressive portal fibrosis accompanying the proliferating bile ducts. As inflammation and necrosis are virtually absent, a significant reduction in liver collagen in this model should allow better selection of true antifibrotic and not merely anti-inflammatory or radical scavenging agents that could be useful in human liver fibrosis.

non-fibrotic controls. However, animals with BDO that received 16 mg PTX exhibited significantly lower liver and spleen weights than the other groups with BDO (p<0.01) (table 1). Similarly, heart and kidney weights were increased in all fibrotic animals (p<0.01), and again lower in the group that received PTX (high) compared with untreated rats with BDO alone (p<0.05, not shown).

Total hepatic collagen content was determined as HYP. BDO for six weeks increased total liver collagen 10-fold (fig 2A). PTX (high) over six weeks reduced liver collagen by 24% (p<0.01). But there was only a trend towards collagen reduction with PTX (low) (p=0.06), and no antifibrotic effect in the group that received PTX (high) from week 4 to week 6—that is, when treatment was started at an already fourfold increased total liver collagen. The relative proportion of collagen (in mg/g liver), which increased threefold after six weeks of BDO, showed a reduction only in the group of rats that received PTX (high) over six weeks (p<0.05) (fig 2B). The quantitative collagen data were confirmed by histological staging using a refined scoring system. Here, the median of the untreated group with BDO reached 3.5 points compared with 2.75 in the group with PTX (high) over six weeks (p<0.05), and 3.25 points in the group with PTX (high) from week 4 to week 6 (NS) (fig 2C). There was no evidence of inflammation and necrosis in any group of fibrotic rats (score of 0). To assess the effect of PTX on hepatic stellate cell/myofibroblast activation, sections were stained for desmin. When we counted the number of desmin positive cells in three high power fields both of (fibrotic) portal tracts and (non-fibrotic) centrilobular areas of each liver, we did not detect significant differences between groups with BDO (not shown).

At sacrifice, serum levels of PIIINP, a surrogate marker of liver fibrogenesis, were increased 11-fold after BDO compared with the sham operated controls. PIIINP was lowered significantly in both groups that received PTX over six weeks (p<0.05) but unchanged in the group treated from week 4 to week 6 (fig 2D).

Hepatic procollagen α1(I), TIMP-1, TGF-β1, CTGF, and GAPDH steady state mRNA levels were determined by multiprobe ribonuclease protection assays. The protected bands showed the expected sizes and there were no equivalent bands in the negative controls. After six weeks of BDO, hepatic procollagen α1(I), TIMP-1 and TGF-β1 mRNA, normalised to GAPDH mRNA, were highly increased relative to the sham operated controls (all p<0.001) (fig 3). PTX downregulated the 20-fold increased procollagen α1(I) mRNA by a factor of eight (p<0.001) whereas it upregulated TIMP-1 mRNA twofold (p<0.05). TGF-β1 and CTGF transcript levels were decreased by approximately 60–70% (fig 3).

Alkaline phosphatase (ALP), gamma glutamyl transpeptidase (γGT), and bilirubin were increased 3.5, 9, and 27-fold, respectively, in the BDO compared with the sham operated animals. These cholestasis parameters were not affected by treatment with PTX (table 1). Similarly, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), reflecting inflammation and necrosis, did not differ among groups except for a moderate elevation in AST in rats that received both doses of PTX for six weeks (p<0.05).

To investigate if one of the serum parameters reflected the decrease in hepatic collagen accumulation in animals treated with PTX, correlations were calculated using the Spearman rank order test (table 2). Liver hydroxyproline correlated well with PTX (high) over six weeks. Data are mean (SD). *p<0.05, **p<0.001 versus untreated group (BDO alone).

**DISCUSSION**

We previously showed that experimental liver fibrosis due to complete obstruction of the biliary tract is a suitable model for testing drugs that inhibit hepatic fibrogenesis in vivo. This model is characterised by a progressive portal fibrosis accompanying the proliferating bile ducts. As inflammation and necrosis are virtually absent, a significant reduction in liver collagen in this model should allow better selection of true antifibrotic and not merely anti-inflammatory or radical scavenging agents that could be useful in human liver fibrosis.
Antifibrotic effect of pentoxifylline in liver fibrosis

Several studies showed that the methylxanthine derivative PTX, an inhibitor of phosphodiesterases, can inhibit mesenchymal cell proliferation and collagen synthesis in vitro.\(^{14-17}\)

Most of these investigations had been performed with dermal fibroblasts but recently several groups confirmed these effects of PTX in rat\(^{18}\) and human hepatic stellate and myofibroblast cell cultures.\(^{19-24}\)

Previous in vivo studies used porcine liver fibrosis subsequent to feeding of yellow phosphorus\(^{13}\) which bears little similarity to human disease, or rat carbon tetrachloride induced fibrosis, a model that involves free radicals and severe necroinflammation of the pericentral zone.\(^{11}\) Importantly, the numbers of animals in these studies were low. A recent report investigated the effect of a single intraperitoneal injection of PTX (50 mg/kg body weight) in rats 24 hours prior to bile duct ligation for only three days.\(^{26}\) The authors demonstrated an antiproliferative effect of PTX on hepatic myofibroblasts in vivo but did not investigate fibrosis. A single study suggested no significant antifibrotic effect of PTX (30 mg/kg/day for four weeks) in rats with bile duct ligation.\(^{26}\) However, lower numbers of animals were used, fibrosis and cholestasis were less advanced, and apart from morphometry, no biochemical collagen determinations or investigations of matrix metabolism were carried out. Therefore, we studied the antifibrotic efficacy of PTX and parameters of matrix turnover in our model of chronic BDO.

We showed that PTX, when given orally at a dose of 16 mg/kg/day, reduced total hepatic collagen accumulation moderately but significantly whereas the effect of half the dose did not reach statistical significance. In contrast with its moderate antifibrotic effect, PTX potently downregulated hepatic steady state levels for procollagen \(\alpha(1)\) mRNA, which encodes the major collagen deposited during fibrogenesis, from 20-fold to 2.5-fold above baseline in bile duct obstructed rats. This eightfold reduction in procollagen \(\alpha(1)\) mRNA is the most dramatic effect of a drug on procollagen I expression in this progressive model of fibrosis and to our knowledge, unmatched in any other in vivo model of hepatic fibrosis. It was shown before that apart from being an antiproliferative drug for mesenchymal cells, PTX also potently suppresses interstitial procollagen expression in vitro.\(^{27,28}\) In rat biliary fibrosis, only silymarin, a mixture of well defined flavonoids, and LU135252, a specific endothelin A receptor antagonist, inhibited collagen accumulation and procollagen \(\alpha(1)\) mRNA expression by up to 60%.\(^{29,30}\) However, in contrast with these two drugs, PTX upregulated expression of TIMP-1, the most important endogenous inhibitor of most matrix metalloproteinases, more than twofold in rats with BDO, whereas silymarin and LU135252 suppressed TIMP-1 three and twofold, respectively. These findings strongly suggest that in vivo, upregulation of TIMP-1 expression by PTX counteracts its powerful suppressive effect on procollagen I expression, resulting in the observed modest net reduction in fibrosis.

While PTX downregulates TIMP-1 in fibroblasts and culture activated hepatic stellate cells,\(^{31}\) it could upregulate TIMP-1 mRNA expression in hepatocytes, bile duct epithelia, and Kupffer cells which do not express procollagen I but significant amounts of TIMP-1 mRNA during fibrogenesis.\(^{32,33}\) Thus our findings caution against extrapolation of in vitro data using activated stellate cells or myofibroblasts alone for the far more complex in vivo situation of fibrogenesis.

The effect of PTX on procollagen I mRNA expression is even more remarkable when we consider that the higher dose of the drug did not exceed the upper dose that is usually prescribed for humans to improve the macro and microcirculation.\(^{34}\) The published plasma levels at this oral dose range from 2 to 5 \(\mu\)g/ml\(^{35}\) and are thus below concentrations that are required to suppress collagen synthesis of activated hepatic stellate cells and myofibroblasts in vitro, reaching 27% (at 100 \(\mu\)g/ml) or

---

### Table 2: Correlations between the investigated parameters. Coefficients were calculated using the Spearman rank order correlation, and highly significant correlations (p<0.01) are printed in bold.

<table>
<thead>
<tr>
<th></th>
<th>BW</th>
<th>Hyp/liver</th>
<th>Liver</th>
<th>Spleen</th>
<th>Kidneys</th>
<th>Heart</th>
<th>AST</th>
<th>ALT</th>
<th>γ-GT</th>
<th>ALP</th>
<th>Bili</th>
<th>Crea</th>
<th>Histo</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIIINP</td>
<td>0.01</td>
<td>0.86</td>
<td>0.63</td>
<td>0.82</td>
<td>0.29</td>
<td>0.29</td>
<td>0.03</td>
<td>0.10</td>
<td>0.40</td>
<td>0.04</td>
<td>0.01</td>
<td>0.23</td>
<td>0.83</td>
</tr>
<tr>
<td>ΔBW</td>
<td>0.09</td>
<td>0.18</td>
<td>0.11</td>
<td>0.31</td>
<td>0.10</td>
<td>-0.40</td>
<td>-0.05</td>
<td>-0.08</td>
<td>-0.04</td>
<td>-0.21</td>
<td>-0.06</td>
<td>0.17</td>
<td></td>
</tr>
<tr>
<td>Hpty/liver</td>
<td>0.80</td>
<td>0.90</td>
<td>0.36</td>
<td>0.42</td>
<td>0.05</td>
<td>0.02</td>
<td>0.24</td>
<td>0.46</td>
<td>0.07</td>
<td>-0.26</td>
<td>0.82</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>0.76</td>
<td>0.40</td>
<td>0.41</td>
<td>0.07</td>
<td>-0.16</td>
<td>0.18</td>
<td>0.27</td>
<td>0.24</td>
<td>-0.13</td>
<td>0.55</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spleen</td>
<td>0.37</td>
<td>0.38</td>
<td>0.01</td>
<td>0.06</td>
<td>0.33</td>
<td>0.39</td>
<td>0.11</td>
<td>-0.28</td>
<td>0.75</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidneys</td>
<td>0.51</td>
<td>0.14</td>
<td>0.11</td>
<td>0.31</td>
<td>0.21</td>
<td>0.02</td>
<td>0.34</td>
<td>0.13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart</td>
<td>0.12</td>
<td>0.08</td>
<td>0.16</td>
<td>0.09</td>
<td>0.01</td>
<td>-0.19</td>
<td>0.35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST</td>
<td>0.46</td>
<td>0.19</td>
<td>0.06</td>
<td>0.29</td>
<td>0.07</td>
<td>0.06</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td>0.35</td>
<td>0.28</td>
<td>0.11</td>
<td>0.12</td>
<td>0.09</td>
<td>0.28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>γ-GT</td>
<td>0.27</td>
<td>0.09</td>
<td>0.28</td>
<td>0.02</td>
<td>0.52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALP</td>
<td>0.01</td>
<td>0.18</td>
<td>0.06</td>
<td>-0.18</td>
<td>0.06</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bili</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**BW**, per cent increase in body weight over the six weeks of the experiment; Hyp, hepatic hydroxyproline (mg); Liver/spleen/kidneys/heart (organ weights in g); AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, gamma glutamyltransferase; ALP, alkaline phosphatase; Bili, total bilirubin; Crea, creatinine; ΔBW, difference in body weight; Histo, histo score (points); Hyp, hydroxyproline; PIIINP, serum aminoterminal propeptide of procollagen type III.

**Figure 4**: Correlations between total liver collagen, aminoterminal propeptide of procollagen type III (PIIINP), and the histo score. Correlations were calculated using the Spearman rank order correlation, as described in the methods.

![Graph A](image1.png)

**r = 0.82/p < 0.01**

![Graph B](image2.png)

**r = 0.86/p < 0.01**

www.gutjnl.com
67% (at 500 μg/ml). In other in vivo experimental settings such as thrombin induced platelet activation, this was explained by an as yet unidentified in vivo accumulation or activation of the drug. At the applied dosage, PTX did not cause hepatic inflammation or necrosis while AST was slightly elevated in the groups that received PTX over six weeks (table 1). Similarly, PTX did not change the laboratory parameters of cholestasis, suggesting that its antifibrotic properties are unrelated to an effect on hepatobiological function but rather due to a direct impact on the effector cells of hepatic fibrogenesis—that is, activated stellate cells and (portal tract derived) myofibroblasts. This is supported by Desmouliere and colleagues who found significantly reduced myofibroblast proliferation and factor XIII a activation in vitro.

Suppression of stellate cells and myofibroblasts by PTX appears to involve at least three different mechanisms that act in part downstream of a rise in intracellular cAMP and (2) enhanced intracellular degradation of procollagen prior to its secretion and extracellular deposition as fibrils; (3) inhibition of platelet derived growth factor induced mitogenicity by interference with the activation of the mitogen activated protein kinase, a central event in the signalling cascade downstream of the activated platelet derived growth factor receptor. Much of the antimitogenic effect of PTX is mediated by protein kinase A which, on activation by cAMP, can phosphorylate and thus deactivate kinases upstream of mitogen activated protein kinase. In addition, PTX blocks nuclear factor κB activation in stimulated Kupffer cells which explains its activity in suppressing nuclear factor κB dependent synthesis and release of tumour necrosis factor α. However, the role of tumour necrosis factor α in fibrogenesis remains equivocal as it enhanced collagen synthesis in bleomycin induced pulmonary fibrosis while increasing matrix metalloproteinase expression in gut intestinal fibrosis. Other antifibrotic pathways induced by PTX are independent of phosphodiesterase activity and involve second messengers such as stat-1 which is also activated by the interferons, cytokines that suppress collagen production, and fibroblast proliferation in vitro.

Phosphodiesterases (PDEs) represent a family of nine isoforms (PDE1–PDE9) and several splice variants. These PDEs act differentially in cells, mainly due to their compartmentalisation and substrate specificity—for example, cAMP for PDE-3 and -4, and c-GMP for PDE-1 and -5. Apart from PTX which inhibits most of the PDE isoforms, and pentifylline that is approximately 10-fold more potent than PTX, some novel drugs block certain PDEs. Examples are sildenafil for PDE-1 and rolipram for PDE-3 that both deactivate the nuclear factor κB-tumour necrosis factor α pathway. More selective PDE inhibitors that preferentially block PDE-3 and -4 are desirable as they could potentially exert a more specific suppressive effect on activated stellate cells and myofibroblasts. Alternatively, PTX could be targeted to the fibrogenic effector cells. That this is now feasible was recently shown by use of a cyclic peptide that recognises the (activation induced) collagen VI receptor on hepatic stellate cells and myofibroblasts.

Serum levels of a surrogate marker of hepatic fibrogenesis, PIINP at sacrifice, correlated with total liver collagen, histological fibrosis score, and with liver spleen weights of fibrotic rats. This is in line with recent data that demonstrated good correlations of PIINP with hepatic steady state levels of procollagen α1(I) and TIMP-1 mRNA levels. Since PIINP, as well as a spectrum of other surrogate markers of liver fibrosis, can be measured in humans, prediction and even titrating of the antifibrotic effect of PTX or any other potential antifibrotic agent on a day to day basis may be possible.

In conclusion, we have shown that PTX, a phosphodiesterase inhibitor with a well known clinical profile, can dramatically downregulate hepatic procollagen I expression in biliary fibrosis. This effect is in part counteracted by upregulation of TIMP-1 which leads to a moderate net reduction in collagen accumulation. PIINP, a surrogate marker of hepatic fibrogenesis, reflects the antifibrotic effect of PTX. More specific inhibitors for certain PDE isoforms, such as PDE-3 and -4, may be more potent antifibrotic agents. Based on these in vivo data, further studies using PDE inhibitors for treatment of hepatic fibrosis are warranted.

ACKNOWLEDGEMENT
Supported in part by a joint grant from the German government and the University of Erlangen-Nuernberg (IZKF B18). DS was a recipient of a Hermann-und-Lilly-Schilling professorship.

Part of this work was presented in abstract form at the meeting of the American Gastroenterological Association, Orlando, Florida, May 16–19, 1999 (Gastroenterology 1999;118:A1227).

Authors’ affiliations
C Raetsch, G Boigk, E-O Riecken, Department of Gastroenterology, University Hospital Benjamin Franklin, Free University of Berlin, Germany J D Jia, Department of Gastroenterology, University Hospital Benjamin Franklin, Free University of Berlin, Germany and First Department of Medicine, University of Erlangen-Nuernberg, Germany
M Bauer, E Hohn, D Schuppan, First Department of Medicine, University of Erlangen-Nuernberg, Germany

REFERENCES
Antifibrotic effect of pentoxifylline in liver fibrosis


29 Jamall IS, Finelli VN, Quee HS. A simple method to determine nanogram levels of hydroxyproline in biological tissues. Anal Biochem 1981;112:70–5.


Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis
C Raetsch, J D Jia, G Boigk, M Bauer, E G Hahn, E-O Riecken and D Schuppan

Gut 2002 50: 241-247
doi: 10.1136/gut.50.2.241

Updated information and services can be found at:
http://gut.bmj.com/content/50/2/241

These include:

References
This article cites 60 articles, 14 of which you can access for free at:
http://gut.bmj.com/content/50/2/241#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Pancreas and biliary tract (1949)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/